Inhibrx Q2 Loss Widens to $36.7M; Cash at $219.5M After Oxford Draw
INBX has more than doubled off its 52-week low of $22.04.
Summary
Inhibrx's Q2 loss widened to $36.7M, but cash reached $219.5M after drawing from its Oxford facility. PFS data for INBRX-106 is expected in Q3 2026.
Key Events · Earnings and Guidance · INBX
-
Q2 Net Loss Widens
Net loss was $36.7 million ($2.34/share) in Q2 2026, up from $28.7 million ($1.85/share) in Q2 2025, driven by higher R&D and pre-commercialization expenses.
-
Cash Position Strengthened
Cash and equivalents were $133.3 million at June 30, 2026, and $219.5 million as of August 6, 2026, after drawing $100 million from the expanded Oxford loan facility.
-
INBRX-106 PFS Data in Q3 2026
Company plans to announce progression-free survival data from the randomized Phase 2 trial in head and neck squamous cell carcinoma in combination with pembrolizumab during Q3 2026.
-
Ozekibart CRC Expansion
Two additional Phase 1 cohorts in colorectal cancer were initiated in Q2 2026; interim results expected in Q1 2027.
Analysis · INBX · Life Sciences
A wider Q2 net loss of $36.7 million, up from $28.7 million a year ago, reflects higher R&D and pre-commercialization spending. The cash position improved to $219.5 million as of August 6 after drawing $100 million from the expanded Oxford loan facility, providing runway into 2027. Key upcoming catalysts include PFS data from the INBRX-106 Phase 2 trial in Q3 2026 and an FDA meeting in Q4 2026 to discuss ozekibart's registrational path in colorectal cancer.
At the time of this filing, INBX was trading at $97.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $22.04 to $155.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.